![]() |
|
|
Department of Metabolic Diseases, Glaxo Wellcome Incorporated, Research Triangle Park, NC 27709
1To whom correspondence and reprint requests should be addressed.
Human immunodeficiency virus (HIV) protease inhibitors (PI) may alter lipid metabolism in patients with acquired immunodeficiency syndrome (AIDS). However, the influence of dietary fat on the metabolic effects of PI therapy remains unknown. AKR/J mice were fed high or low fat diets and treated with the PI indinavir (IDV), nelfinavir (NFV), saquinavir (SQV) or amprenavir (APV) by subcutaneous delivery for 2 wk. Serum concentrations of glucose, insulin, triglyceride, free fatty acid, glycerol, pancreatic lipase, bilirubin, alkaline phosphatase, blood urea nitrogen and PI, and interscapular and epididymal fat weights were determined. Some metabolic effects of PI were dependent on diet. IDV- and NFV-treated mice had greater serum glucose concentration and body weight; IDV-treated mice had lower serum insulin; NFV-treated mice had greater interscapular fat mass; and SQV treated mice had lower serum triglyceride concentration than control mice fed the low but not the high fat diet. In contrast, NFV- and IDV-treated mice had greater triglyceride concentration and blood urea nitrogen, and SQV treated mice had greater serum cholesterol than control mice fed the high but not the low fat diet. The serum concentration of SQV was lower in mice fed the high fat compared with the low fat diet. Other effects were not dependent on diet. IDV- and NFV-treated mice had greater fatty acids, and IDV-treated mice had greater pancreatic lipase, bilirubin and alkaline phosphatase than control mice fed either diet. APV treatment had little effect on these serum measurements. Thus, changes in dietary fat can influence some but not all of the effects of PI on metabolism. Furthermore, each PI produces different effects in vivo, indicating that various PI affect distinct metabolic pathways.
KEY WORDS: dyslipidemia fat HIV protease inhibitors lipodystrophy
This article has been cited by other articles:
![]() |
J. A. Perez-Molina, P. Domingo, E. Martinez, and S. Moreno The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy J. Antimicrob. Chemother., August 1, 2008; 62(2): 234 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Balasubramanyam, H. Mersmann, F. Jahoor, T. M. Phillips, R. V. Sekhar, U. Schubert, B. Brar, D. Iyer, E. O. Smith, H. Takahashi, et al. Effects of transgenic expression of HIV-1 Vpr on lipid and energy metabolism in mice Am J Physiol Endocrinol Metab, January 1, 2007; 292(1): E40 - E48. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Huang, C. Brown, W. Ni, E. Maynard, A. C. Rigby, and P. Oettgen Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis Blood, April 15, 2006; 107(8): 3153 - 3160. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Xu, S. Yin, L. Wong, K. Weng Chan, and K. S. L. Lam Adiponectin Ameliorates Dyslipidemia Induced by the Human Immunodeficiency Virus Protease Inhibitor Ritonavir in Mice Endocrinology, February 1, 2004; 145(2): 487 - 494. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Hruz, H. Murata, H. Qiu, and M. Mueckler Indinavir Induces Acute and Reversible Peripheral Insulin Resistance in Rats Diabetes, April 1, 2002; 51(4): 937 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Lenhard, D. K. Croom, J. E. Weiel, and D. A. Winegar HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis Arterioscler. Thromb. Vasc. Biol., December 1, 2000; 20(12): 2625 - 2629. [Abstract] [Full Text] [PDF] |
||||